Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor (vol 76, pg 89, 2013)

被引：3
|
作者：
Kubitza, D.
Roth, A.
Becka, M.
Alatrach, A.
Halabi, A.
Hinrichsen, H.
Mueck, W.
机构：
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2013年 / 76卷 / 03期
关键词：
D O I：
10.1111/bcp.12215
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：489 / 489
页数：1
相关论文
共 50 条
  • [1] Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor
    Kubitza, Dagmar
    Roth, Angelika
    Becka, Michael
    Alatrach, Abir
    Halabi, Atef
    Hinrichsen, Holger
    Mueck, Wolfgang
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (01) : 89 - 98
  • [2] Pharmacokinetics and Pharmacodynamics of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor
    Kreutz, Reinhold
    CURRENT CLINICAL PHARMACOLOGY, 2014, 9 (01): : 75 - 83
  • [3] Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
    Kubitza, Dagmar
    Becka, Michael
    Mueck, Wolfgang
    Halabi, Atef
    Maatouk, Haidar
    Klause, Norbert
    Lufft, Volkmar
    Wand, Dominic D.
    Philipp, Thomas
    Bruck, Heike
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (05) : 703 - 712
  • [4] Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects
    Jiang, Ji
    Hu, Yufang
    Zhang, Jianyan
    Yang, Jueling
    Mueck, Wolfgang
    Kubitza, Dagmar
    Bauer, Richard J.
    Meng, Ling
    Hu, Pei
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (01) : 234 - 241
  • [5] Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor in healthy subjects
    Mueck, W.
    Becka, M.
    Kubitza, D.
    Voith, B.
    Zuehlsdorf, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (06) : 335 - 344
  • [6] The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor
    Kubitza, Dagmar
    Becka, Michael
    Roth, Angelika
    Mueck, Wolfgang
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (03): : 249 - 255
  • [7] Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - Are not affected by aspirin
    Kubitza, Dagmar
    Becka, Michael
    Mueck, Wolfgang
    Zuehlsdorf, Michael
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 981 - 990
  • [8] Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
    Frost, Charles
    Wang, Jessie
    Nepal, Sunil
    Schuster, Alan
    Barrett, Yu Chen
    Mosqueda-Garcia, Rogelio
    Reeves, Richard A.
    LaCreta, Frank
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (02) : 476 - 487
  • [9] Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects
    Zhao, Xia
    Sun, Peihong
    Zhou, Ying
    Liu, Yuwang
    Zhang, Huilin
    Mueck, Wolfgang
    Kubitza, Dagmar
    Bauer, Richard J.
    Zhang, Hong
    Cui, Yimin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (01) : 77 - 88
  • [10] Assessment of factor Xa chromogenic assays for measuring the pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor
    Perzborn, E.
    Hardwardt, M.
    Samama, M. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 379 - 380
12345